MEI Pharma, Inc.

    MEI Pharma, Inc.

    NNASDAQ:MEIP
    2.60
    USD
    +0.04
    (+1.56%)
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    12.63
    0.78
    1.38
    6.09
    6.18
    6.54
    7.33
    9.8
    - -
    - -
    Basic EPS, GAAP
    -22.02
    -27.06
    -23.18
    -12.13
    1.45
    -19.34
    -4.73
    -10.36
    -7.34
    -8.75
    -4.78
    2.67
    - -
    -2.39
    Free Cash Flow per Basic Share
    -19.84
    -19.44
    -19.91
    -10.38
    1.87
    -10.15
    -8.33
    7.33
    -5.81
    -7.91
    -7.88
    -7.58
    - -
    -3.13
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1.75
    - -
    - -
    Book Value per Share
    -189.55
    -123.07
    -110.72
    -102.91
    -94.71
    -103.5
    -65
    -61.13
    -56.82
    -60.12
    -60.93
    -58.26
    - -
    -60.66
    Tangible Book Value per Share
    67.72
    44.62
    42.11
    24
    27.44
    24.22
    13.4
    16.92
    8.79
    8.42
    3.7
    4.96
    - -
    2.54
    Basic Weighted Avg Shares
    1
    1
    1
    2
    2
    2
    4
    5
    6
    6
    7
    7
    - -
    7
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    23
    2
    5
    28
    35
    41
    49
    65
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    10.25
    -1,762.39
    -940.9
    -92.58
    -173.65
    -185.48
    -75.31
    38.96
    - -
    - -
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Net Income, GAAP
    -11
    -27
    -33
    -21
    3
    -40
    -17
    -47
    -41
    -54
    -32
    18
    -16
    -16
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    0.04
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    11.48
    -2,470.28
    -342.2
    -169.96
    -118.73
    -133.8
    -65.22
    27.23
    - -
    - -
    Working Capital
    34
    45
    59
    41
    50
    96
    68
    195
    145
    143
    87
    32
    17
    17
    LT Debt
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    7
    9
    11
    - -
    - -
    - -
    Total Equity
    35
    45
    60
    42
    51
    50
    48
    77
    49
    52
    25
    33
    17
    17
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    5.15
    - -
    - -
    - -
    - -
    - -
    - -
    72.3
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    -1.52
    - -
    - -
    - -
    - -
    - -
    - -
    -4.55
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'25
    Mar'25
    Jun'25
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    7
    7
    7
    Market Capitalization
    16
    15
    16

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'25
    Mar'25
    Jun'25
    Total Current Assets
    24
    21
    18
    Cash, Cash Equivalents & STI
    24
    20
    18
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    2
    1
    1
    Payables & Accruals
    1
    - -
    - -
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    -5.08%
    -19.5%
    -48.73%
    Free Cash Flow
    -124.28%
    -40.63%
    -58.71%
    Net Income, GAAP
    -199.49%
    -73.53%
    -189.69%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    9
    33
    6
    1
    49
    2024
    65
    - -
    - -
    - -
    65
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -2.49
    1.54
    -2.32
    - -
    -4.78
    2024
    8.46
    -1.66
    -1.37
    - -
    2.67
    2025
    -1.2
    -0.4
    -0.39
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    1.75
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • businesswire.com

      MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'

    • thenewswire.com

      BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

    • businesswire.com

      MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

    • benzinga.com

      Why Is MEI Pharma Stock Soaring On Friday?

    • businesswire.com

      MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

    • businesswire.com

      MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

    • businesswire.com

      MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

    • businesswire.com

      MEI Pharma Reports Fiscal Year End 2024 Cash Position

    • businesswire.com

      MEI Pharma to Consider Strategic Alternatives

    • investorplace.com

      7 Undervalued Biotech Stocks to Buy for Big-Time Returns

    • https://www.defenseworld.net

      National Bank of Canada FI Takes $36,000 Position in MEI Pharma, Inc. (NASDAQ:MEIP)

    • businesswire.com

      Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

    • businesswire.com

      MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

    • businesswire.com

      MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

    • businesswire.com

      MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

    • businesswire.com

      Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

    • zacks.com

      MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates

    • businesswire.com

      MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

    • businesswire.com

      MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

    • businesswire.com

      Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)